Skip to content
Open access

New CLA3+/4 scores predict outcomes in MASLD.

Nov 2026 · JHEP Reports · pp. 102074 · 0 citations · 49 references
Medicine

Abstract

Background

&

Aims

Fibrosis is a major determinant of adverse outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD). We developed and validated two probability scores for advanced fibrosis (≥F3) and cirrhosis (F4)-CLA3+ and CLA4-using controlled attenuation parameter (CAP), liver stiffness (LS) by vibration-controlled transient elastography (VCTE), and alanine aminotransferase (ALT), and evaluated their prognostic values for liver-related events (LREs).

Methods

In a 16-center multinational cohort, single-term fractional-polynomial logistic regression models derived CLA3+ and CLA4 probabilities. Prognostic performance was assessed using time-dependent area under the receiver operating characteristic curve (AUROC), Brier score, integrated discrimination improvement (IDI), and serial-change analyses.

Results

The derivation cohort included 2,811 biopsied patients; validation included 11,196 patients with baseline VCTE, of whom 8,046 had serial assessments. Derivation AUROCs were 0.84 for CLA3+ and 0.89 for CLA4. In validation, both achieved the highest integrated AUROC (0.83) and lowest integrated Brier scores (0.0078-0.0081) among non-invasive tests, with good calibration. CLA3+ classified 83.1%/10.8%/6.1% as low/intermediate/high risk (5-year LRE 0.4%/1.5%/11.8%; sensitivity 0.72), whereas CLA4 classified 92.0%/3.6%/4.4% (0.5%/4.7%/13.0%; specificity 0.93), with the smallest intermediate-risk groups. IDI favored CLA3+ over Agile3+, whereas CLA4 performed similarly to Agile4. Serial risk categories remained stable in 86.7% for CLA3+ and 93.2% for CLA4, while ≥10-30% decreases were associated with lower LRE risk. Two-step testing reduced intermediate classifications to 3.9% with FIB-4→CLA3+ and 1.4% with FIB-4→CLA4, with a 5-year LRE rate of 8.3% in the rule-in group.

Conclusions

CLA3+ and CLA4 provide well-calibrated estimates for advanced fibrosis and cirrhosis using controlled attenuation parameter, liver stiffness, and alanine aminotransferase, with small intermediate-risk groups and prognostically informative serial changes. They may serve as second-line tests within Fibrosis-4 index-based two-step pathways. IMPACT AND IMPLICATIONS Current MASLD care pathways use sequential non-invasive testing to identify patients at risk of advanced fibrosis and liver-related events, but existing composite scores often require multiple clinical inputs and leave substantial intermediate-risk groups. CLA 3+ and CLA 4 use CAP, liver stiffness, and ALT to achieve prognostic performance comparable to Agile scores, while yielding small intermediate-risk groups and informative serial changes. These findings support their potential use as simple second-line tools after FIB-4 and for longitudinal risk assessment in VCTE-based pathways, with relevance to clinical triage and future trial design.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.